ConductScience.org, home

Comparison · NCT01235546-c06378e9

Placebo and Standard of Care vs Azithromycin and Standard of Care: Neonatal Intensive Care Unit (NICU) Admission

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Placebo and Standard of Care vs Azithromycin and Standard of Care: Neonatal Intensive Care Unit (NICU) Admission. Trial comparisons, record NCT01235546-c06378e9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01235546-c06378e9

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.170.1480.195wilson
Risk in group 20.1680.1460.192wilson
Risk difference, group 1 minus group 20.00239-0.03040.0352newcombe hybrid score
Risk ratio, group 1 over group 21.010.8361.23log
Odds ratio, group 1 over group 21.020.8061.28log
Number needed to treat, for one more participant with the outcome on Placebo and Standard of Care than on Azithromycin and Standard of Care419from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Placebo and Standard of Care250 cc normal saline~Placebo: 250 cc normal saline and Standard of care (cefazolin or clindamycin)169992OG000
Group 2Azithromycin and Standard of CareAzithromycin: 500 mg in 250 cc normal saline 1 time dose and Standard of care (cefazolin or clindamycin)1711,018OG001

Outcome

Type
OTHER_PRE_SPECIFIED
Title
Neonatal Intensive Care Unit (NICU) Admission
Description
Neonates who are admitted to the NICU due to morbidities diagnosed from birth and up to three months of life. Morbidities as defined in the Neonatal morbidities outcome measure.
Time frame
Up to 3 months after birth
Population

Source ClinicalTrials.gov

Trial

Title
Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection
NCT number
NCT01235546
Phases
NA
Conditions
Endometritis, Wound Infection, Abscess, Surgical Site Infection
Interventions
Azithromycin and standard of care, Placebo and standard of care
Lead sponsor
Alan Tita
Results first posted
2017-07-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01235546-c06378e9